-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, FZlxQO59xcsT+00KUHOEGYdN4IxXaeNCTPeO2SZRzL1D5y3rGF5BIbnGWiKhSAh2 ZwsmMwcTaqinw+kIaQjXZA== 0001144204-09-027373.txt : 20090515 0001144204-09-027373.hdr.sgml : 20090515 20090515150602 ACCESSION NUMBER: 0001144204-09-027373 CONFORMED SUBMISSION TYPE: 13F-HR PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20090331 FILED AS OF DATE: 20090515 DATE AS OF CHANGE: 20090515 EFFECTIVENESS DATE: 20090515 FILER: COMPANY DATA: COMPANY CONFORMED NAME: RA CAPITAL MANAGEMENT, LLC CENTRAL INDEX KEY: 0001346824 IRS NUMBER: 830406777 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 13F-HR SEC ACT: 1934 Act SEC FILE NUMBER: 028-12884 FILM NUMBER: 09832215 BUSINESS ADDRESS: STREET 1: 800 BOYLSTON STREET, SUITE 1500 CITY: BOSTON STATE: MA ZIP: 02199 BUSINESS PHONE: 617-778-2500 MAIL ADDRESS: STREET 1: 800 BOYLSTON STREET, SUITE 1500 CITY: BOSTON STATE: MA ZIP: 02199 13F-HR 1 v149296_13f-hr.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 13F FORM 13F COVER PAGE Report for the Calendar Year or Quarter Ended: March 31, 2009 Check here if Amendment [ ]; Amendment Number: ___________ This Amendment (Check only one): [ ] is a restatement. [ ] adds new entries. Institutional Investment Manager Filing this Report: Name: RA Capital Management, LLC ------------------------------------- Address: 800 Boylston Street, Suite 1500 ------------------------------------- Boston, MA 02199 ------------------------------------- Form 13F File Number: 28-12884 -------------- The institutional investment manager filing this report and the person by whom it is signed hereby represent that the person signing the report is authorized to submit it, that all information contained herein is true, correct and complete, and that it is understood that all required items, statements, schedules, lists, and tables, are considered integral parts of this form. Person Signing this Report on Behalf of Reporting Manager: Name: Peter Kolchinsky ------------------------------------- Title: Manager ------------------------------------- Phone: (617) 778-2500 ------------------------------------- Signature, Place, and Date of Signing /s/ Peter Kolchinsky Boston, MA May 15, 2009 - -------------------------- -------------------------- ---------------------- [Signature] [City, State] [Date] Report Type (Check only one): [X] 13F HOLDINGS REPORT. (Check here if all holdings of this reporting manager are reported in this report.) [ ] 13F NOTICE. (Check here if no holdings reported are in this report, and all holdings are reported by other reporting manager(s).) [ ] 13F COMBINATION REPORT. (Check here if a portion of the holdings for this reporting manager are reported in this report and a portion are reported by other reporting manager(s).) List of Other Managers Reporting for this Manager: NONE FORM 13F SUMMARY PAGE Report Summary: Number of Other Included Managers: 0 ----------------- Form 13F Information Tabel Entry Total: 14 ----------------- Form 13F Information Table Value Total: 188,020 ----------------- (thousands) List of Other Included Managers: NONE FORM 13F INFORMATION TABLE
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8 - ---------------------------- --------- ----------- -------- ------------------------- ---------- -------- --------------------- TITLE OF VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY NAME OF ISSUER CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGERS SOLE/ SHARED/NONE - ------------------------------------------------------------------------------------------------------------------------------------ AMAG PHARMACEUTICALS INC COM 00163U 10 6 11,221 305,163 SH SOLE N/A 305,163 ANADYS PHARMACEUTICALS INC COM 03252Q 40 8 2,239 329,725 SH SOLE N/A 329,725 ARDEA BIOSCIENCES INC COM 03969P 10 7 11,991 1,165,262 SH SOLE N/A 1,165,262 BIOSPECIFICS TECHNOLOGIES CO COM 090931 10 6 16,624 810,931 SH SOLE N/A 810,931 CARDIOME PHARMA CORP COM NEW 14159U 20 2 1,286 438,915 SH SOLE N/A 438,915 CUBIST PHARMACEUTICALS INC COM 229678 10 7 4,908 300,000 SH SOLE N/A 300,000 DENDREON CORP COM 24823Q 10 7 578 137,500 SH SOLE N/A 137,500 ENTEROMEDICS INC COM 29365M 10 9 1,122 824,742 SH SOLE N/A 824,742 NORTHSTAR NEUROSCIENCE INC COM 66704V 10 1 3,572 1,870,229 SH SOLE N/A 1,870,229 PHARMASSET INC COM 71715N 10 6 7,462 760,694 SH SOLE N/A 760,694 SEQUENOM INC COM NEW 817337 40 5 85,132 5,986,780 SH SOLE N/A 5,986,780 SEQUENOM INC COM NEW 817337 40 5 30,328 2,132,800 SH CALL SOLE N/A N/A VANDA PHARMACEUTICALS INC COM 921659 10 8 1,817 2,019,170 SH SOLE N/A 2,019,170 VERTEX PHARMACEUTICALS INC COM 92532F 10 0 9,741 339,044 SH SOLE N/A 339,044
-----END PRIVACY-ENHANCED MESSAGE-----